Terms ending in 2027
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,859,568 | Pyrrolo[3,2-d]pyrimidin-4-one Derivatives and Their Use in Therapy In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 8,387,615 | Inhaler Cap Strap In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,051,851 | Inhaler for the Administration of Powdered Pharmaceuticals, and a Powder Cartridge System for Use with This Inhaler In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,501,698 | Crystal Structures of SGLT2 Inhibitors and Processes for Preparing Same In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 7,829,707 | Pyrrolo [3,2-d]pyrimidin-4-one Derivatives and Their Use in Therapy In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US D685,460 | Tablet In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 8,063,073 | 2-Pyridone Derivatives as Neutrophil Elastase Inhibitors and Their Use In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,026,396 | Processes for the Preparation of Optically Active Intermediates In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,278,475 | Processes for the Preparation of Optically Active Intermediates In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,859,570 | Maleate Salts of a Quinazoline Derivative Useful as an Antiangiogenic Agent In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| 6 more term ends in 2027 · Pro | |||||
10 of 16 patents shown. Soonest term end first, then patent number.
Pro members see all 16, all of them expiring within the 18 months from Nov 17, 2026.
14 of these are in force and held by AstraZeneca AB.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.